Retension’s ‘Dream Team’ Aims to Revive a Drug for Resistant Hypertension

FALLS CHURCH, VA – September 14, 2026 – In the high-stakes world of drug development, a company’s credibility is often measured by the minds it can attract. Retension Pharmaceuticals, a clinical-stage biotech, has just made a significant move on that front, announcing the formation of a Scientific Advisory Board (SAB) stacked with some of the most respected names in cardiovascular medicine. While press releases about advisory boards are common, this one signals a calculated strategy to de-risk a promising asset and tackle one of modern medicine’s most persistent problems: uncontrolled hypertension.

The company's lead candidate, RTN-001, is not a new discovery but a compound with a history, now being given a second chance. By assembling a board of top-tier physicians and researchers, Retension is signaling to investors, regulators, and the medical community that it is marshalling every available resource to succeed where others have not. This is more than a corporate milestone; it's a critical look at the system of innovation, where a drug's fate can depend as much on the team behind it as the molecule itself.

Assembling the 'Who's Who' of Hypertension

Retension’s newly formed SAB reads like a who's who of hypertension and cardiology. The five inaugural members are leaders from globally recognized institutions like Harvard Medical School, the Cleveland Clinic, Mount Sinai, and the University of Cambridge. Their collective expertise spans hypertension diagnosis, cardiorenal disease, and the intricate design of the very clinical trials that will determine RTN-001’s future.

Members include Dr. Randall M. Zusman, Director of the Division of Hypertension at Massachusetts General Hospital, and Dr. Omar Al Dhaybi, who directs the American Heart Association Comprehensive Hypertension Center at Mount Sinai. The board also features Dr. Ian Wilkinson, President of the British and Irish Hypertension Society, and Dr. James L. Januzzi, a Harvard professor and Chief Scientific Officer at the Baim Institute for Clinical Research. Crucially, the board includes Dr. Luke J. Laffin from the Cleveland Clinic, who not only brings his expertise but also serves as the Chair of the Steering Committee for the ongoing Phase 2b trial of RTN-001. This dual role creates a powerful synergy between high-level strategic guidance and on-the-ground trial execution.

“The formation of this Scientific Advisory Board reflects both the caliber of clinical and scientific leadership we have been able to bring to the RTN-001 program,” said Eric Keller, Chief Executive Officer of Retension Pharmaceuticals. He noted that these advisors have helped shape the modern understanding of hypertension and its devastating impact on the heart and kidneys.

The strategic value of such a board cannot be overstated. For a small company like Retension, which has raised $25.4 million in venture funding, the endorsement of these experts serves as a powerful validation of its scientific approach. It provides the “clinical rigor to pursue a therapy built for patients whose current treatments fail,” as Chief Medical Officer Alison D. Schecter, M.D., put it. Their guidance is expected to sharpen not only the execution of the current trial but also the long-term vision for where RTN-001 could fit into the future of cardiovascular care.

The Second Act for a Promising Compound

The story of RTN-001 is a fascinating case study in pharmaceutical strategy. The drug is a next-generation PDE5 inhibitor being developed under an exclusive worldwide license from Sanofi, one of the world's largest pharmaceutical companies. This immediately raises a question: why would a pharma giant out-license a promising asset? The answer often lies in strategic portfolio management. Large companies frequently shelve or divest compounds that fall outside their core focus areas, creating opportunities for smaller, more specialized biotechs to carry the torch.

This is where Retension’s leadership team provides a unique narrative thread. CEO Eric Keller and Chief Scientific Officer Paul Sweetnam have a deep history with RTN-001. The compound was originally discovered at a company called Surface Logix, where Sweetnam was a key scientist. Keller later led the acquisition of Surface Logix and its assets. While one of those assets, RezuRock, was ultimately developed and is now marketed by Sanofi, RTN-001 took a different path, eventually being licensed back from Sanofi to the very team that knows it best. This isn't just a business transaction; it's a mission to finish what they started, giving the drug a second act.

This model—a nimble biotech reviving a shelved asset from big pharma—is a cornerstone of the modern innovation ecosystem. It allows promising science to find the right home, potentially unlocking value that was otherwise dormant. With a recently issued U.S. patent extending its intellectual property protection through at least 2044, Retension is well-positioned to capitalize on this second chance.

Targeting a Silent and Stubborn Killer

The ultimate goal for Retension and its new advisors is to address a massive unmet need. Nearly half of all adults in the U.S. have hypertension, and for a significant portion, the condition remains uncontrolled despite the availability of numerous medications. A particularly challenging group suffers from “resistant hypertension,” where blood pressure remains dangerously high even with treatment from three or more drugs. This relentless pressure damages vital organs, leading to heart failure, stroke, and chronic kidney disease.

RTN-001 aims to tackle this by improving upon a known mechanism. As a PDE5 inhibitor, it works by enhancing nitric oxide signaling, which helps relax blood vessels. However, unlike first-generation drugs in this class, RTN-001 is designed to be a “cardiovascular-targeted” agent that preferentially acts on the central arteries, a core driver of hypertension. The company believes this tissue-targeted approach can deliver clinically meaningful blood pressure reductions where other drugs have fallen short.

The competitive landscape is heating up. In March 2024, the FDA approved Idorsia’s Tryvio, the first new class of oral hypertension drug in decades. Other novel mechanisms, including aldosterone synthase inhibitors and RNAi agents, are also advancing through late-stage trials. Retension is betting that RTN-001’s targeted mechanism, combined with a convenient once-daily formulation, can carve out a crucial place in this evolving market.

The Road Ahead: A High-Stakes Clinical Trial

All of this strategic positioning now converges on a single point: the ongoing Phase 2b clinical trial (NCT07142356). The study is enrolling approximately 280 patients with uncontrolled hypertension who are already on two to five medications. They will be randomized to receive one of three doses of RTN-001 or a placebo for 12 weeks. The primary goal is to see if the drug can deliver a statistically significant and clinically meaningful reduction in blood pressure.

This trial is the crucible where the scientific premise, the second-act narrative, and the expert guidance of the new SAB will be put to the test. The study’s design, which includes measuring central and ambulatory blood pressure, reflects the sophisticated approach needed to prove a drug's value in this complex patient population. With the trial underway, the guidance from the SAB will be instrumental in navigating the challenges of clinical development and interpreting the results. The world will be watching for the topline data, which will determine if this dream team can help deliver a much-needed new weapon against a silent killer.